Bosse, D, Ades, E W · Journal of clinical & laboratory immunology · 1989
This study looked at whether adding a immune-boosting substance called IL-2 to a blood treatment (gammaglobulin) could help the body's immune cells better fight cells infected with Epstein-Barr virus. The researchers found in laboratory tests that IL-2 did enhance this immune response, and they suggested it might help ME/CFS patients who receive gammaglobulin treatment.
Since some ME/CFS patients have elevated EBV antibodies and abnormal immune responses, understanding how to enhance immune cells' ability to target infected cells is clinically relevant. This early mechanistic work provides a rationale for investigating immunotherapeutic approaches that combine gammaglobulin with IL-2 in ME/CFS populations.
This study does not prove that IL-2 works in actual patients—it only demonstrates laboratory activity in cultured cells. It does not establish whether EBV is a primary cause of ME/CFS, nor does it show that this combined treatment would be safe or effective in humans. The findings represent a preliminary hypothesis requiring clinical validation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →